Abstract
Introduction: Cannabis use disorders are highly prevalent in patients with schizophrenia and other psychoses, and are probably associated with a range of poor outcomes. Several trials have been conducted on this population, the results of which have been summarized in several systematic reviews but never in meta-analyses specifically regarding cannabis use.
Methods: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched using predefined search terms. We included randomized trials of all types of interventions targeting cannabis use disorders in patients with schizophrenia spectrum disorders. We extracted information on intervention types, efficacy, trial characteristics, and risk of bias.
Results: There was no evidence of an effect on frequency of cannabis use, but intervention effects of motivational intervention with or without cognitive behavior therapy were observed on quantity of use and on positive symptoms of schizophrenia. Psychosocial intervention did not have an appreciable effect on negative symptoms. Longer interventions appear to be more efficacious, and efficacy may be better in trials with comparatively few women. Larger trials may be better at establishing effects on positive symptoms.
Conclusion: Psychosocial interventions appear moderately efficacious in reducing quantity of cannabis-use and positive symptoms.
Keywords: Cannabis, schizophrenia, meta-analysis.
Current Pharmaceutical Design
Title:Intervention Efficacy in Trials Targeting Cannabis Use Disorders in Patients with Comorbid Psychosis Systematic Review and Meta-analysis
Volume: 20 Issue: 13
Author(s): Carsten Rygaard Hjorthoj, Amanda Baker, Allan Fohlmann and Merete Nordentoft
Affiliation:
Keywords: Cannabis, schizophrenia, meta-analysis.
Abstract: Introduction: Cannabis use disorders are highly prevalent in patients with schizophrenia and other psychoses, and are probably associated with a range of poor outcomes. Several trials have been conducted on this population, the results of which have been summarized in several systematic reviews but never in meta-analyses specifically regarding cannabis use.
Methods: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched using predefined search terms. We included randomized trials of all types of interventions targeting cannabis use disorders in patients with schizophrenia spectrum disorders. We extracted information on intervention types, efficacy, trial characteristics, and risk of bias.
Results: There was no evidence of an effect on frequency of cannabis use, but intervention effects of motivational intervention with or without cognitive behavior therapy were observed on quantity of use and on positive symptoms of schizophrenia. Psychosocial intervention did not have an appreciable effect on negative symptoms. Longer interventions appear to be more efficacious, and efficacy may be better in trials with comparatively few women. Larger trials may be better at establishing effects on positive symptoms.
Conclusion: Psychosocial interventions appear moderately efficacious in reducing quantity of cannabis-use and positive symptoms.
Export Options
About this article
Cite this article as:
Hjorthoj Rygaard Carsten, Baker Amanda, Fohlmann Allan and Nordentoft Merete, Intervention Efficacy in Trials Targeting Cannabis Use Disorders in Patients with Comorbid Psychosis Systematic Review and Meta-analysis, Current Pharmaceutical Design 2014; 20 (13) . https://dx.doi.org/10.2174/13816128113199990431
DOI https://dx.doi.org/10.2174/13816128113199990431 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Chemical Constituents and Pharmacological Actions of Silybum Marianum
Current Nutrition & Food Science Nutritional Supplements Modulating Metabolic Syndrome Risk Factors and the Prevention of Cardiovascular Disease
Current Nutrition & Food Science The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets The Potential of PDE4 Inhibitors in Respiratory Disease
Current Drug Targets - Inflammation & Allergy Editorial [Hot topic: An Overview on the Design, Development, Characterization and Applications of Novel Nanomedicines for Brain Targeting (Guest Editor: Eliana B. Souto)]
Current Nanoscience GMP-Automated Purification of Copper-61 Produced in Cyclotron Liquid Targets: Methodological Aspects
Current Radiopharmaceuticals Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Amyloid β Peptide Levels Increase in Brain of AβPP Swedish Mice after Exposure to Chlorpyrifos
Current Alzheimer Research Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Biological Therapies in Osteoarthritis
Current Pharmaceutical Design Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Preterm Infant Swallowing and Respiration Coordination During Oral Feeding: Relationship to Dysphagia and Aspiration
Current Pediatric Reviews Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews Characterization of Lin-ve CD34 and CD117 Cell Population Reveals an Increased Expression in Bone Marrow Derived Stem Cells
Current Neurovascular Research The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued)